United Therapeutics Corporation
Symbol: UTHR
NASDAQ
262.4
USDMarket price today
11.7399
P/E Ratio
-0.0998
PEG Ratio
11.64B
MRK Cap
- 0.00%
DIV Yield
United Therapeutics Corporation (UTHR) Stock Split, History Data
Working capital analysis
In terms of working capital, United Therapeutics Corporation maintains a healthy position. The total current assets of the company are valued at $3551000000. This represents a growth rate of 5.050% compared to the previous year. Breaking down the current assets, the cash and investments are worth $1207700000, exhibiting a growth rate of 25.645% year-on-year. The receivables, another significant portion of the current assets, are valued at $278900000. The year-on-year growth rate for receivables is 26.543%. The inventory, which forms a critical part of the assets, is valued at $111800000. This represents a healthy year-on-year growth of 9.608% On the liabilities side, the company's current liabilities total $804400000. This reflects a growth rate of 134.382% over the previous year, indicating the company's financial obligations are well under control.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|
Cash and investments | 1207.70 | 961.20 | ||||
Receavebles | 278.90 | 220.40 | ||||
Inventory | 111.80 | 102.00 | ||||
Other | 166.20 | 219.20 | ||||
Total Current Assets | 3551.00 | 3380.30 | ||||
Acc Payable | 5.60 | 4.10 | ||||
Short Term Debt | 400.00 | 0.00 | ||||
Other Current Liab | 71.00 | 339.10 | ||||
Current Liabilities | 804.40 | 343.20 |
Capital Structure
When examining the capital structure of United Therapeutics Corporation, it is clear that the company manages a robust portfolio. The value of their total assets clocks in at $6495200000. When juxtaposed with the previous year, this marks a growth rate of 2.351%, showcasing the company's ability to steadily grow its asset base. Turning to liabilities, the company has total liabilities amounting to $1157100000. Compared to the prior year, this reflects a growth rate of -5.373%. The long-term debt forms a sizable part of these liabilities, coming in at $200000000. Over the last year, the long-term debt has grown by -75.000%. On the asset side, the cash and equivalent reserves are worth $1251500000. The year-on-year growth of these reserves is 7.563%. The company's common stock, another important asset, holds a value of $700000, growing at a rate of 0.000% from the previous year. Finally, the company's retained earnings stand at $6333700000, marking a growth rate of 19.884% year-over-year. These earnings represent the profits that United Therapeutics Corporation has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$6,495.20
Total liabilities
$1,157,100,000.00
Long term debt
$200.00
Cash and eqv
$1,251,500,000.00
Goodwill
$0.00
Retained earnings
$6,333,700,000.00
Common stock
$0.00
Enterprise Value
$8.37
Net earnings per share (EPS)
United Therapeutics Corporation has an EPS of $6.52, which signifies the profit allocated per share of common stock. With a growth rate of -69.041% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years | Q1 | Q2 | Q3 | Q4 | Total |
---|---|---|---|---|---|
2024 | 6.52 | - | - | - | 6.52 |
2023 | 5.2 | 5.53 | 5.71 | 4.62 | 21.06 |
2022 | 5.03 | 2.41 | 4.91 | 2.88 | 15.23 |
2021 | 0.63 | 3.85 | 3.62 | 2.49 | 10.59 |
2020 | 3.14 | 2.43 | 3.86 | 2.22 | 11.65 |
2019 | -11.32 | 4.68 | 3.02 | 1.2 | -2.42 |
2018 | 5.65 | 4.01 | 2.44 | 1.5 | 13.60 |
2017 | 4.01 | -1.25 | 6.37 | 0.44 | 9.57 |
2016 | 5.19 | 4.65 | 3.75 | 2.61 | 16.20 |
2015 | -0.36 | 2.15 | 10.2 | 2.29 | 14.28 |
2014 | 2.73 | 2.35 | -0.53 | 2.44 | 6.99 |
2013 | 1.24 | 1.6 | 1.25 | -0.61 | 3.48 |
2012 | 1.32 | 1.37 | 1.52 | 1.66 | 5.87 |
2011 | 0.28 | 1.27 | 1.45 | 0.81 | 3.81 |
2010 | 0.35 | 0.67 | 0.7 | 0.17 | 1.89 |
2009 | 0.25 | -0.0442 | 0.22 | -0.0608 | 0.37 |
2008 | 0.26 | 0.32 | 0.24 | -1.53 | -0.71 |
2007 | -0.0653 | 0.14 | 0.35 | 0.044 | 0.46 |
2006 | 0.05 | 0.17 | 0.19 | 1.3 | 1.71 |
2005 | 0.17 | 0.27 | 0.35 | 0.63 | 1.42 |
2004 | -0.0433 | 0.095 | 0.14 | 0.15 | 0.35 |
2003 | -0.0723 | -0.0565 | -0.0316 | -0.0756 | -0.24 |
2002 | -0.14 | -0.0775 | -0.29 | -0.0623 | -0.57 |
2001 | -0.23 | -0.26 | -0.24 | -0.18 | -0.91 |
2000 | -0.22 | -0.78 | -0.18 | -0.78 | -1.96 |
1999 | -0.4 | -0.26 | -0.2 | -0.24 | -1.10 |
United Therapeutics Corporation (UTHR) stock split history
Understanding the historical stock splits of United Therapeutics Corporation (UTHR) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on September 23, 2009 with a ratio of 2:1. Throughout its history, the company has undergone 1 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.
Date | Split Ratio |
---|---|
23 September 2009 | 2:1 |
Frequently Asked Question
What is the latest historical split date of the company?
The latest historical split date is N/A.
What is firm free cah flow per share (FCF per share)?
The free cah flow per share (FCF per share) is 16.009.
What is company revenue per share?
The company revenue per share is 0.503.
What are firm earnings per share?
The firm earnings per share is 0.761.
What is United Therapeutics Corporation (UTHR) ROIC (return on capital)?
United Therapeutics Corporation (UTHR) ROIC (return on capital) is 0.223.
What is dividend per share figure?
The dividend per share is 0.000
What is enterprise plowback ratio?
United Therapeutics Corporation (UTHR) plowback ratio is N/A
What is firm enterprise value (EV)?
The enterprise value (EV) is 8.371
What is company debt to equity ratio?
The debt to equity ratio is 0.112
What are debt ratio numbers?
The debt ratio is 0.092
What is company price to sales ratio?
The price to sales ratio is 4.660